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Abstract
Background: Although much has been published for the development of cell lines, these were lab
based and developed for scientific technical staff.
Objective of review: We discuss the ethical implications of tissue retention and present a generic
consent form (Part II). We also present a simple and successful protocol for the development of
cell lines and tissue harvesting for the clinical scientist (Part I).
Conclusion: Consent is also more proximate and assurance can be given of appropriate usage.
Ethical questions concerning tissue ownership are in many institutions raised during the current
consenting procedure. We provide a robust ethical framework, based on the current legislation,
which allows clinicians to be directly involved in cell and tissue harvesting.
Background
In this molecular diagnostic age, we have a duty to our
patients to try to advance and improve treatment. One of
the main areas of research nowadays is related mainly to
cell cultures [1-7] and their applications increases every-
day.
Advances are dependent upon and limited by the availa-
bility of sufficiently high quality tissue samples for analy-
sis by DNA, mRNA and expressed protein assays [8-10].
The limitations may be caused by restrictions in the scope
of patient consent [11], rarity of the disease, diversity of
tumour types, method of storage and inadequate docu-
mentation [9,10,12].
Although much has been published for the development
of cell lines [1-7], these were lab based and developed for
scientific technical staff. We, however, present a simple
and successful protocol for the development of cell lines
and tissue harvesting for the clinical scientist (see Part I).
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Our aim is to enhance the quality of translational research
to the benefit of our future patients.
In this section (Part II) we discuss the ethics implications of
tissue retention and present a generic consent form, which
maybe adapted to suit individual institutions. The Human
Tissue Act 2004 [11,13,14] provides a detailed statutory
framework for tissue use but does not resolve the issues of
ownership and of how much information should be dis-
closed to those consenting and how specific the consent
should be [11], we hope to provide a framework within
which this legalisation could be ethically adhered to.
Methods
The Human Tissue Act 2004 [13] and Human Tissue Act
2006 (Scotland) [14] were passed following inquiries into
the storage of children's organs and tissue without the
proper consent. The Acts make consent [15-17] central to
the lawful storage and use of children and young people's
organs and tissue, and to the removal of such material
after death. The Human Tissue Authority [14] regulates
and issues codes of practice on activities covered by the
Act in England, Wales and Northern Ireland. Scottish min-
isters have those powers in Scotland [15,18].
The taking of fully informed consent is more complicated
than is commonly realised [11,13-15,17-21], (Appendix 1).
Many of the previous guidelines involved obtaining a waiver
from the patient at the time of consent for the potential com-
mercial exploitation of their tissues by third parties with no
direct personal gain for the donor. This may be akin to the
exchange of precious artefacts for shiny beads; a familiar and
often employed historical practice by which many of the
early European and American settlers 'duped' native popula-
tions. This waiver may be worth in the order of many billions
in currency and has now been successfully legal contested. As
clinicians we have to be tirelessly cautious and honest to act
in our patients 'true' best interests and not just be the confi-
dence inspiring face that in times of personal crisis for of the
vulnerable patient gets them to sign away their rights. An eth-
ical approach however does not preclude considerable phar-
maceutical profits or future investment in research and
development, despite what we are commonly led to believe
even as shareholders. Furthermore, complicity if proven may
result in erase by our licensing bodies, since we may not have
acted in our patients' best interests [13,15,18].
Consent for removal of tumour tissue during a surgical proce-
dure should be distinct from consent for the retention of the
tissues for future use in research for specified uses [22,23].
Two contrasting and non-coherent common law principles
apply to the consent for surgery to remove samples and the
new legislation regarding the storage and use of samples.
The consent to the procedure must be obtained from the
person who has decision making capacity or in some cases
parental responsibility if the test of capacity (Gillick)
[9,16] is not passed although good practice would indi-
cate that all parties involved should be in agreement
(Appendix 1). Explaining the complex relationships
between patient care, research and commercial biotech-
nology to the patient and their family during the consent-
ing process to a surgical procedure with its attendant
practical and emotional difficulties could be particularly
challenging [9,18,22,23].
The needs for treatment have priority over the needs for
research samples [23]. Individual clinical practices of mul-
tiple biopsies to reduce sampling errors and procedure
repetition may lead to excess tissue but this cannot be
guaranteed for research [9,10,23].
Tissue banking is of importance where the studies of
tumours of low incidence (i.e. head and neck tumours)
restrict the potential for large collections of tissues in
small centres [24,25]. The types of samples collected
would include solid tumours, normal tissue adjacent to
the tumour, biopsies blood and bone marrow aspirates as
well as extracted nucleic acids [25].
Many challenges will be faced by those running tissue
banks this includes the need to respond to the ever chang-
ing law regarding this domain [13,15,22,24,25].
Complications arise because samples stored for research
may remain after treatment is completed. Despite this it
could be argued that the sizes of samples taken for
research are small and there is no apparent current risk to
the patient from the storage of tissues for research.
Unfortunately, with the advances in technology the idea
that a tissue sample is really made anonymous by simple
removal of patient details is now fallacious [25]. This is
because with DNA fingerprinting all samples can now
potentially be identified. Should this data be inviolate
even against the vagaries of the law which may later dic-
tate the sharing of all databases? There would be further
implications for storage of paediatric tissue [22,23]. Once
again just because sharing of tissue data is made legal this
does not mean it is morally right or ethical.
The possibility of misuse imposes a responsibility of proper
management and protection to the subjects' interests.
Informed consent is required for all types of DNA banking.
Objective ethical committee oversight is required to ensure an
acceptable balance between risks and benefits [24,25].
Results
Consent may differ for new and existing collections.
a) For new collections consent should be written and spe-
cific protection should be provided for vulnerable sub-International Archives of Medicine 2009, 2:9 http://www.intarchmed.com/content/2/1/9
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jects, populations based on the principles of acting in
their best interests. Individuals are informed of the types
of research that will or might be carried out, whom should
have access and the duration of storage. Consent should
be freely given and be free of pressure and based on the
validated information given by trained staff.
b) For existing collections, knowing that new technology
allows patient identification from just DNA samples and
that no true anonymisation can exist, the issues become
more pertinent. Investigators should be obligated to re-
contact subjects to obtain consent for new studies. Where
impracticable new tissues should be sought [25]. Tissues
should not be bartered for treatment which should be con-
sidered a proxy for the illegal organ trade. Post-mortem
specimens should not be used if no consent was obtained.
Commercial banks should be regulated and severely cen-
sured if they infringe agreed stipulations [9,12,14].
While protecting confidentiality, the free circulation and
availability of genetic information and samples for
research should be promoted [9,12,23].
The underlying principles which should apply:-
a) The subject should always be considered as the primary
controlled of its DNA and clinical information directly
derived from it. Once processed this information becomes
research data with joint private ownership [24,25]. The clini-
cian should be considered the patients advocate and custo-
dian of the DNA/genetic data. As such they should take all
appropriate steps to protect the data, its storage and access. It
follows that the intellectual property should be that of the
patient but with due consideration for benefit sharing. If a
researcher or concern does not agree to these terms, market
forces dictate that one that will agree may become available
because of the 'precious' nature of the material [23].
b) For data already anonymised where it is not feasible to
obtain patient consent, the material should be considered
abandoned. It would be ethical to destroy the material
and seek fresh samples.
c) The potential for future or actual financial exploitation
of tissues for researchers/commerce creates an ethical
imbalance for donor specific returns. A joint relationship
obviates this inequity.
d) Use by third parties may be allowed provided there is
no transfer in ownership of data or that derived.
Ethics and consent
Research and ethical approval is ideally obtained with
regards the consent and subsequent tissue use. The volun-
tary nature of the process must be emphasized and no
form of duress implied, ideally the process is carried out
well ahead of any procedure. We present our current con-
sent form for modification and usage (Additional file 1).
Prospective patient data is entered on a proforma or
directly into a database detailing i.e. family history, carci-
nogenic exposure, TNM stage (with volumetric staging),
previous and proposed treatment and duration with later
entry of prognostic, morbidity and mortality data. A note
is made of the anonymised patient sample number. These
anonymised records are held in a secure computer and
written form.
Discussion & Conclusion
We present a simple and successful protocol for the devel-
opment of cell lines and tissue harvesting. It does not
require high technology and can be performed by most
clinicians in most hospitals. Rates of tissue registration at
banks have been affected by the controversies surround-
ing the retention of human tissues and legal and ethical
uncertainties [22,23]; we hope to provide an ethical and
technical basis to reverse this trend.
The advantages of hospital based cell line creation are
numerous. We can be more certain that cell lines are
developed from the particular tissues of interest and accu-
rate anatomical and appropriate clinico-pathological con-
trol tissues are also harvested.
Consent is also more proximate and assurance can be
given of appropriate usage. Ethical questions concerning
tissue ownership are in many institutions raised during
the current consenting procedure [25]. Does the patient in
his desire to cooperate with his doctor during cancer treat-
ment really understand the ramifications of agreeing to
the use of their tissues for research and potentially very
lucrative drug development by third parties? Are they not
put under undue influence? Do we as the clinicians
directly dealing with the patient not have a duty of care to
protect their interests rather than devolving responsibility
to other organizations and committees who do not pos-
sess this overriding agenda [16,18].
The commercialisation of therapeutic products contain-
ing regenerative human tissue is regulated by the common
law, statute and ethical guidelines in Australia and Eng-
land, Wales and Northern Ireland. Brown and Then exam-
ined the regulatory regimes in these jurisdictions and
considered whether reform is required to both support
scientific research and ensure conformity with modern
social views on medical research and the use of human tis-
sue. The authors considered the crucial role of informed
consent in striking the balance between the interests of
researchers and the interests of the public [26].
Again, no current consenting procedure outlines this
administrative area. When most patients consent for theirInternational Archives of Medicine 2009, 2:9 http://www.intarchmed.com/content/2/1/9
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tissues to be used, it is in direct reference to the doctor
taking the consent and tissue. Perhaps as doctors, we
should not be eager to overlook this point and perhaps
use this to direct research into more clinically relevant
areas to enhance translational utility. Problems further
arise in the laboratory situation where such a precious
resource is at a premium. When one operates there is a
personal and professional trust between the patient and
doctor, perhaps this should be extended to the research
realm. Patients do not expect their tissues to be sold or
offered to profit making organizations even if this is
decided 'in-proxy' by tissue bank committee [24,25].
Should each separate use of patient's tissue require further
direct patient consent? Despite these concerns, it is not
difficult to imagine an equitable process whereby the use
of patient samples are followed (traced) and if found val-
uable the patient have a direct share of the royalties from
this. Similar to the entertainment industry and repeat per-
formance royalty payments.
Currently when a tissue bank is created, it becomes an
extremely valuable resource where many conflicting non-
patient centred issues often occur. Even a tissue bank com-
mittee made up invariably of interested parties cannot
truly be said to represent an individual patients view,
(despite an often inclusion of a lay membership).
Morrin et al. reported the development of a central
resource of consented cancer tissues for researchers to use
for ethically approved projects. Most donors (99.6%) con-
sented to allow access to medical records; 98.3% to tissue
being sent overseas, 97.4% to commercial research and
35.6% requested disposal with a karakia. The predomi-
nant tissues are from donors with cancers of the breast,
colon, urological, and gynaecological sites. they con-
cluded that the tissue bank (in Christchurch) is a success-
ful model, providing quality tissue samples for cancer
research whilst appropriately addressing ethical, legal,
and cultural aspects of their collection [8].
Philosophically, the agreement of an ethical approval
committee does not necessarily mean that the act or proc-
ess is ethical; examples exist where later evidence contra-
dicts or overturns a local decision. Presently it is felt that
selling or bartering of tissue is unethical even when car-
ried out by non profit making organizations. Further-
more, for the consenting procedure to be full and ethical,
it should represent an agreement of intent between the
patient and his clinician only. The samples remain the
non-transferable property of the patient only and their use
directed by the harvesting doctor and pathologist after
agreement with the patient. The samples should be used
for a specific purpose, excess material is destroyed [11,17].
In research and drug development tissue samples are akin
to 'gold-dust' and must be treated as such, i.e. not wasted
for lack of taking and not abused. Any other scenario
would welcome litigation. Public private partnerships still
mean that any drug which is developed is still in license
and the money comes from the public coffers. Lack of
business insight on behalf of the scientists and clinicians
should not be overcome by short term financial gain or
inducements offered by commercial interests.
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Appendices
Appendix 1: Summary of relevant UK legislation
Mental Capacity Act 2005: 5 Statutory Principles 
[18,20,21]
Subjects assumed to have capacity unless it is established
that they lack the capacity
Subjects cannot be treated as unable to make a decision
unless all practicable steps to help them do so have been
taken without success.
Unwise decisions do not mean incapacity to make deci-
sions
All decisions under the Act for a subject who lacks capacity
must be done in their best interests
All decisions must be made in such a way as to be least
restrictive to the patient and maximise the available their
future choices.
'Gillick competence' for patient under 18 years old 
[17,22,23]
The subject has the maturity and intelligence to under-
stand the nature and implications of treatment as assessed
by the doctor.
The subject can consent to treatment if competent.
The subject may not be able to decline treatment if found
to incompetent.
Principles of Robust Consent [12,13,16-19,24]
Presume capacity and discuss risks, complications and
benefits in an open and honest manner in a way designed
to ensure patient understanding.
Ensure potential relevant future events and alternative
actions are considered.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
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Provide options that would be least restrictive to the sub-
ject's future choices.
Ensure decisions are voluntary.
Respect the subject's decision and right to change their
decision.
Additional material
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